Literature DB >> 20653086

Incidence and outcomes of out-of-hospital cardiac arrest with shock-resistant ventricular fibrillation: Data from a large population-based cohort.

Tomohiko Sakai1, Taku Iwami, Osamu Tasaki, Takashi Kawamura, Yasuyuki Hayashi, Hiroshi Rinka, Yasuo Ohishi, Tomoyoshi Mohri, Masafumi Kishimoto, Tatsuya Nishiuchi, Kentaro Kajino, Hisatake Matsumoto, Toshifumi Uejima, Masahiko Nitta, Chizuka Shiokawa, Hisashi Ikeuchi, Atsushi Hiraide, Hisashi Sugimoto, Yasuyuki Kuwagata.   

Abstract

BACKGROUND: The increasing survival rates after out-of-hospital cardiac arrests (OHCA) are due mainly to improvements in the first 3 steps of the chain of survival. The aim of this study was to describe the temporal trends of OHCA incidence and outcomes with shock-resistant ventricular fibrillation (VF) requiring advanced life support procedures.
METHODS: All our subjects were persons aged 18 years or more who had suffered OHCA of presumed cardiac etiology, were witnessed by bystanders, treated by emergency medical service (EMS), and had VF as initial rhythm. Our study was conducted in Osaka Prefecture, Japan from May 1, 1998 through December 31, 2006. Data were collected by EMS personnel using an Utstein-style database. We evaluated the temporal trends of incidence and outcomes of shock-resistant VF.
RESULTS: During the study period, there were 8782 witnessed OHCA cases of presumed cardiac etiology. Among them, 1733 had VF as an initial rhythm, 392 of whom were shock-resistant. While the age-adjusted annual incidence of witnessed VF increased from 2.0 to 3.3 per 100,000 inhabitants, that of shock-resistant VF underwent little change during the study period. The proportion of shock-resistant VF among witnessed VF decreased from 37.0% to 19.0%. Neurologically intact 1-month survival rates after shock-resistant VF remained low at 5.6% even in 2006.
CONCLUSION: The actual incidence of shock-resistant VF has remained unchanged, and their outcomes continue to be dismal. Further efforts are required to reduce the mortality rates of such shock-resistant VF to achieve improved survival after OHCA.

Entities:  

Mesh:

Year:  2010        PMID: 20653086     DOI: 10.1016/j.resuscitation.2010.04.015

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  10 in total

1.  Energy conserving chemical defibrillation of ventricular fibrillation: A randomized two phase controlled blinded trial.

Authors:  Keith A Marill; David D Salcido; Matthew L Sundermann; Allison C Koller; James J Menegazzi
Journal:  Resuscitation       Date:  2016-03-31       Impact factor: 5.262

2.  Prehospital Double Defibrillation for Refractory Ventricular Fibrillation: A Scoping Review Protocol.

Authors:  Dennis Miraglia; Lourdes A Miguel
Journal:  J Innov Card Rhythm Manag       Date:  2020-06-15

Review 3.  The Evolving Role of Esmolol in Management of Pre-Hospital Refractory Ventricular Fibrillation; a Scoping Review.

Authors:  Dennis Miraglia; Lourdes A Miguel; Wilfredo Alonso
Journal:  Arch Acad Emerg Med       Date:  2020-02-25

4.  Feasibility of prehospital esmolol for refractory ventricular fibrillation.

Authors:  Casey Patrick; Remle P Crowe; Brad Ward; Ali Mohammed; Kelley Rogers Keene; Robert Dickson
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-04-09

5.  The first case series analysis on efficacy of esmolol injection for in-hospital cardiac arrest patients with refractory shockable rhythms in China.

Authors:  Rui Lian; Guochao Zhang; Shengtao Yan; Lichao Sun; Wen Gao; Jianping Yang; Guonan Li; Rihong Huang; Xiaojie Wang; Renyang Liu; Guangqing Cao; Yong Wang; Guoqiang Zhang
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

6.  Actual treatments for out-of-hospital ventricular fibrillation at critical care medical centers in Osaka: a pilot descriptive study.

Authors:  Tomohiko Sakai; Tetsuhisa Kitamura; Taku Iwami; Yasuyuki Hayashi; Hiroshi Rinka; Yasuo Ohishi; Tomoyoshi Mohri; Masafumi Kishimoto; Ryosuke Kawaguchi; Kentaro Kajino; Tetsuya Yumoto; Toshifumi Uejima; Masahiko Nitta; Tatsuya Nishiuchi; Chizuka Shiokawa; Taro Irisawa; Osamu Tasaki; Hiroshi Ogura; Yasuyuki Kuwagata; Takeshi Shimazu
Journal:  Acute Med Surg       Date:  2014-03-13

7.  Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.

Authors:  Jasmeet Soar; Katherine M Berg; Lars W Andersen; Bernd W Böttiger; Sofia Cacciola; Clifton W Callaway; Keith Couper; Tobias Cronberg; Sonia D'Arrigo; Charles D Deakin; Michael W Donnino; Ian R Drennan; Asger Granfeldt; Cornelia W E Hoedemaekers; Mathias J Holmberg; Cindy H Hsu; Marlijn Kamps; Szymon Musiol; Kevin J Nation; Robert W Neumar; Tonia Nicholson; Brian J O'Neil; Quentin Otto; Edison Ferreira de Paiva; Michael J A Parr; Joshua C Reynolds; Claudio Sandroni; Barnaby R Scholefield; Markus B Skrifvars; Tzong-Luen Wang; Wolfgang A Wetsch; Joyce Yeung; Peter T Morley; Laurie J Morrison; Michelle Welsford; Mary Fran Hazinski; Jerry P Nolan
Journal:  Resuscitation       Date:  2020-10-21       Impact factor: 5.262

8.  Impact of early intravenous amiodarone administration on neurological outcome in refractory ventricular fibrillation: retrospective analysis of prospectively collected prehospital data.

Authors:  Dong Keon Lee; Yu Jin Kim; Giwoon Kim; Choung Ah Lee; Hyung Jun Moon; Jaehoon Oh; Hae Chul Yang; Han Joo Choi; Young Taeck Oh; Seung Min Park
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2019-12-10       Impact factor: 2.953

9.  Successful resuscitation of refractory ventricular fibrillation with double sequence defibrillation.

Authors:  SungJoon Park; Jung-Youn Kim; Young-Duck Cho; Eusun Lee; Bosun Shim; Young-Hoon Yoon
Journal:  Acute Crit Care       Date:  2020-10-21

10.  Efficacy of AutoPulse for Mechanical Chest Compression in Patients with Shock-Resistant Ventricular Fibrillation.

Authors:  Jarosław Gorący; Paweł Stachowiak; Arkadiusz Krejczy; Patrycja Piątek; Iwona Gorący
Journal:  Int J Environ Res Public Health       Date:  2022-02-23       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.